| 
| On-Demand Webinar: Clinical Adjudication Survey Results Revealed In a recent survey, 89% of clinical adjudication users agreed clinical adjudication provides value to clinical trials. Why? Because using unbiased experts to evaluate a drug or device against predetermined criteria helps determine patient safety and clinical efficacy. Join two experts for a discussion of these and other survey results to understand how they could impact your studies. View Now. |
- Merck, Pfizer, Lilly and J&J restored funding to legislators who stoked Jan. 6 Capitol attack, watchdog says
- Hackers hit Broward Health network, potentially exposing data on 1.3M patients, staff
- Pfizer, BioNTech team up again, taking a swing at GSK's Shingrix dominance
- Thermo Fisher nets cell and gene protein producer PeproTech for $1.85B
- FDA, working through pandemic backlog, pauses US factory inspections on omicron concerns
- AbbVie latest drugmaker to impose 340B restrictions on sales to contract pharmacies
- Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues
- GE, Boston Scientific team up to bring advanced cardiac care tech to Southeast Asia
- Catalent, still buzzing with pandemic momentum, taps COO Maselli to succeed Chiminski as chief executive
- Owlet, Kiddo ramp up remote health monitoring offerings for babies and children
- Fierce is looking for the biggest Rising Stars in Health Tech
- Annexon shares dip 30% as patient dropouts dog midphase Huntington's trial
- NorthShore, Edward-Elmhurst's 9-hospital merger creates Illinois' 3rd-largest system
Featured Story | By Kevin Dunleavy Pharma companies that said they would cut off campaign funds to those in Congress who fomented the Jan. 6 riots by voting against certifying the presidential election results have quickly changed their stance, according to a report by Accountable.U.S. Merck, Eli Lilly, Pfizer and Johnson & Johnson were cited by the watchdog group. read more |
| |
|---|
|
| 
| Webinar: A Collaborative Approach to Complex Chemistry Wednesday, January 12, 2022 | 11am ET / 8am PT Complex therapeutics demand complex chemistry expertise. Discover how the right partner can help you overcome complex chemistry challenges through extensive experience, specialised technologies, and true scientific collaboration. Register now. |
Top Stories By Heather Landi Hackers breached the computer networks of Broward Health in October and may have accessed personal and financial information on more than 1.3 million patients and staff. read more By Annalee Armstrong GlaxoSmithKline has successfully overtaken the shingles vaccine market once owned by Merck, but enter king Pfizer. The Big Pharma juggernaut has signed a third deal with COVID-19 vaccine partner BioNTech, this time to develop an mRNA-based shingles vaccine, in a deal worth $225 million upfront to BioNtech. read more By Conor Hale Thermo Fisher Scientific started off the new year with a new member to its family, closing a $1.85 billion acquisition to build out its recombinant protein catalog. read more By Fraiser Kansteiner The FDA has put certain inspection operations on hold through Jan. 19 as it works “to ensure the safety of its employees and those of the firms it regulates” in the face of omicron. The pause began last Wednesday, shortly before the New Year, and will last for at least two more weeks. read more By Robert King AbbVie became the third drugmaker in recent months to impose restrictions on sales of 340B-discounted products to covered entities' contract pharmacies. read more By Annalee Armstrong Ultragenyx Pharmaceutical and partner GeneTx Biotherapeutics have been given the go-ahead to up the dose in a phase 1/2 Angelman syndrome trial of antisense treatment GTX-102 that was previously paused after some patients temporarily lost the ability to walk. read more By Andrea Park GE Healthcare has been in a collaborative mood as of late, striking a spate of partnerships in the last six months with a goal of improving various facets of clinical care. read more By Fraiser Kansteiner On July 1, Catalent's current president and chief operating officer Alessando Maselli will take up the mantle of chief executive officer. He'll succeed long-time CEO John Chiminski, who's slated to become executive chair of the CDMO's board of directors. read more By Andrea Park Both Owlet and Kiddo kicked off the new year with an eye toward growth—in the form of a new product launch for the former and the largest venture funding round yet for the latter. read more By Conor Hale,Heather Landi We’re searching for the engineers and designers who are looking to deliver on the beneficial potential of AI and new technologies in healthcare. read more By Annalee Armstrong Annexon found out the hard way that investors do read the fine print. Despite the small biotech reporting “promising” interim results from a midphase Huntington’s disease trial, the company saw its shares plummet 30%. read more By Dave Muoio Temporarily known as NorthShore – Edward-Elmhurst Health, the combined system expects to see over $5 billion in first-year revenue. read more |
|
